Skip to main content
Ain-Shams Journal of Anesthesiology

Table 8 Clinical outcome variables

From: Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

 

Terlipressin group (n = 50)

Placebo group (n = 50)

P value

ICU stay (hours)

50.4 ± 10.2

52.7 ± 11.5

0.2927

Hospital Stay (days)

9.8 ± 1.3

10.3 ± 1.5

0.0780

AKI (n)

2

4

0.6777

Major adverse CV events (n)

3

5

0.7150

Mortality (n)

0

1

1

  1. n number of patients, AKI acute kidney injury defined as at least two fold increase in serum creatinine level, or decrease in GFR > 50%, or decreased urine output less than 0.5 mL.kg−1.h−1 for 12 h
  2. Mean ± SD
  3. Major adverse cardiovascular events included non-fatal MI, unstable angina pectoris, heart failure, significant arrhythmia, stroke, new cardiac surgery, or percutaneous coronary intervention
  4. P value is significant when P < 0.05
Back to article page